Ilan Y, Ben Ya'acov A, Shabbat Y, Gingis-Velitski S, Almon E, Shaaltiel Y. Oral administration of a non-absorbable plant cell-expressed recombinant anti-TNF fusion protein induces immunomodulatory effects and alleviates nonalcoholic steatohepatitis. World J Gastroenterol 2016; 22(39): 8760-8769 [PMID: 27818591 DOI: 10.3748/wjg.v22.i39.8760]
Corresponding Author of This Article
Yaron Ilan, MD, Gastroenterology and Liver Units, Department of Medicine, Hadassah Hebrew University Medical Center, Ein-Karem, POB 1200, Jerusalem IL91120, Israel. ilan@hadassah.org.il
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
research-article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Ilan Y, Ben Ya'acov A, Shabbat Y, Gingis-Velitski S, Almon E, Shaaltiel Y. Oral administration of a non-absorbable plant cell-expressed recombinant anti-TNF fusion protein induces immunomodulatory effects and alleviates nonalcoholic steatohepatitis. World J Gastroenterol 2016; 22(39): 8760-8769 [PMID: 27818591 DOI: 10.3748/wjg.v22.i39.8760]
World J Gastroenterol. Oct 21, 2016; 22(39): 8760-8769 Published online Oct 21, 2016. doi: 10.3748/wjg.v22.i39.8760
Oral administration of a non-absorbable plant cell-expressed recombinant anti-TNF fusion protein induces immunomodulatory effects and alleviates nonalcoholic steatohepatitis
Yoseph Shaaltiel, Einat Almon, Svetlana Gingis-Velitski, Yehudit Shabbat, Ami Ben Ya'acov, Yaron Ilan
Yaron Ilan, Ami Ben Ya'acov, Yehudit Shabbat, Gastroenterology and Liver Units, Department of Medicine, Hadassah Hebrew University Medical Center, Jerusalem IL91120, Israel
Author contributions: All authors contributed to the conception, experiments, writing and final approval of the manuscript.
Supported byProtalix Biotherapeutics and The Roman-Epstein Liver Research Foundation (in part).
Conflict-of-interest statement: Ilan Y is a consultant for Protalix, Gingis-Velitski S, Almon E, Shaaltiel Y are employees of Protalix. The study was supported in part by Protalix, Israel.
Correspondence to: Yaron Ilan, MD, Gastroenterology and Liver Units, Department of Medicine, Hadassah Hebrew University Medical Center, Ein-Karem, POB 1200, Jerusalem IL91120, Israel. ilan@hadassah.org.il
Telephone: +972-2-6778231
Received: May 25, 2016 Peer-review started: May 27, 2016 First decision: July 13, 2016 Revised: July 21, 2016 Accepted: August 5, 2016 Article in press: August 5, 2016 Published online: October 21, 2016 Processing time: 147 Days and 19.2 Hours
Core Tip
Core tip: The BY-2 plant cell-expressed recombinant anti-tumor necrosis factor alpha (TNF) fusion protein (PRX-106) that consists of the soluble form of the human TNF receptor fused to the Fc component of a human IgG1 domain was orally administered in high-fat diet model. Altered distribution of CD4+CD25+FoxP3+ and a decrease in the intrasplenic-to-intrahepatic CD8+CD25+FoxP3+ ratio were observed. These effects were associated with a decrease in serum triglyceride levels, decrease in the aspartate aminotransferase levels, serum glucose levels, and HOMA-IR score. A decrease in hepatic triglycerides content was observed in the high dose-treated mice. The data suggest that PRX-106 may provide an oral immunotherapy for nonalcoholic steatohepatitis.
